185 related articles for article (PubMed ID: 35083934)
1. Pharmacogenomic prescribing opportunities in percutaneous coronary intervention and bone marrow transplant patients.
Ratner L; Zhu J'; Gower MN; Patel T; Miller JA; Cipriani A; Stouffer GA; Crona DJ; Lee CR
Pharmacogenomics; 2022 Feb; 23(3):183-194. PubMed ID: 35083934
[No Abstract] [Full Text] [Related]
2. Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients.
Black RM; Williams AK; Ratner L; Crona DJ; Wiltshire T; Weck KE; Stouffer GA; Lee CR
Pharmacogenomics; 2020 May; 21(7):431-441. PubMed ID: 32343201
[No Abstract] [Full Text] [Related]
3. Prospective
Tuteja S; Glick H; Matthai W; Nachamkin I; Nathan A; Monono K; Carcuffe C; Maslowski K; Chang G; Kobayashi T; Anwaruddin S; Hirshfeld J; Wilensky RL; Herrmann HC; Kolansky DM; Rader DJ; Giri J
Circ Genom Precis Med; 2020 Feb; 13(1):e002640. PubMed ID: 31928229
[TBL] [Abstract][Full Text] [Related]
4. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
[TBL] [Abstract][Full Text] [Related]
5. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.
Dong OM; Wheeler SB; Cruden G; Lee CR; Voora D; Dusetzina SB; Wiltshire T
Value Health; 2020 Jan; 23(1):61-73. PubMed ID: 31952675
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population.
Verma SS; Keat K; Li B; Hoffecker G; Risman M; ; Sangkuhl K; Whirl-Carrillo M; Dudek S; Verma A; Klein TE; Ritchie MD; Tuteja S
J Transl Med; 2022 Nov; 20(1):550. PubMed ID: 36443877
[TBL] [Abstract][Full Text] [Related]
8. Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID-19: A Retrospective Multicenter Study in the United States.
Stevenson JM; Alexander GC; Palamuttam N; Mehta HB
Clin Transl Sci; 2021 Jan; 14(1):153-162. PubMed ID: 33085221
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention.
Fragoulakis V; Bartsakoulia M; Díaz-Villamarín X; Chalikiopoulou K; Kehagia K; Ramos JGS; Martínez-González LJ; Gkotsi M; Katrali E; Skoufas E; Vozikis A; John A; Ali BR; Wordsworth S; Dávila-Fajardo CL; Katsila T; Patrinos GP; Mitropoulou C
Pharmacogenomics J; 2019 Oct; 19(5):438-445. PubMed ID: 30647444
[TBL] [Abstract][Full Text] [Related]
10. Prescription medications with actionable pharmacogenomic recommendations in Veterans Health Administration patients.
Maghari S; Gallo T; Rivas S; German A; Nguyen Le MQ; Abbaszadegan H; Zubriski MA; Heise CW; Landas ND
Pharmacogenomics; 2023 Jun; 24(9):501-508. PubMed ID: 37435738
[No Abstract] [Full Text] [Related]
11. Clinical Outcomes and Sustainability of Using
Lee CR; Sriramoju VB; Cervantes A; Howell LA; Varunok N; Madan S; Hamrick K; Polasek MJ; Lee JA; Clarke M; Cicci JD; Weck KE; Stouffer GA
Circ Genom Precis Med; 2018 Apr; 11(4):e002069. PubMed ID: 29615454
[TBL] [Abstract][Full Text] [Related]
12. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
[TBL] [Abstract][Full Text] [Related]
13. Description of Pharmacogenomic Testing Among Patients Admitted to the Intensive Care Unit After Cardiovascular Surgery.
Peterson PE; Nicholson WT; Moyer AM; Arendt CJ; Smischney NJ; Seelhammer TG; Krecke CA; Haney RM; Yaw EJ; Chlan LL
J Intensive Care Med; 2021 Nov; 36(11):1281-1285. PubMed ID: 32734840
[TBL] [Abstract][Full Text] [Related]
14. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients.
Dong OM; Li A; Suzuki O; Oni-Orisan A; Gonzalez R; Stouffer GA; Lee CR; Wiltshire T
Pharmacogenomics; 2018 Jun; 19(9):771-782. PubMed ID: 29793377
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
Limdi NA; Cavallari LH; Lee CR; Hillegass WB; Holmes AM; Skaar TC; Pisu M; Dillon C; Beitelshees AL; Empey PE; Duarte JD; Diaby V; Gong Y; Johnson JA; Graves J; Garbett S; Zhou Z; Peterson JF;
Pharmacogenomics J; 2020 Oct; 20(5):724-735. PubMed ID: 32042096
[TBL] [Abstract][Full Text] [Related]
16. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
AlMukdad S; Elewa H; Al-Badriyeh D
J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
[TBL] [Abstract][Full Text] [Related]
17. Attitudes toward pharmacogenetics in patients undergoing
Lee G; Varughese LA; Conway L; Stojinski C; Ashokkumar S; Monono K; Matthai W; Kolansky DM; Giri J; Tuteja S
Per Med; 2022 Mar; 19(2):93-101. PubMed ID: 34984913
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care Setting.
Cohn I; Manshaei R; Liston E; Okello JBA; Khan R; Curtis MR; Krupski AJ; Jobling RK; Kalbfleisch K; Paton TA; Reuter MS; Hayeems RZ; Verstegen RHJ; Goldman A; Kim RH; Ito S
JAMA Netw Open; 2021 May; 4(5):e2110446. PubMed ID: 34037732
[TBL] [Abstract][Full Text] [Related]
19. Retrospective Review of Pharmacogenetic Testing at an Academic Children's Hospital.
Roberts TA; Wagner JA; Sandritter T; Black BT; Gaedigk A; Stancil SL
Clin Transl Sci; 2021 Jan; 14(1):412-421. PubMed ID: 33048453
[TBL] [Abstract][Full Text] [Related]
20. Drug Prescribing and Outcomes After Pharmacogenomic Testing in a Developmental and Behavioral Health Pediatric Clinic.
Patel JN; Mueller MK; Guffey WJ; Stegman J
J Dev Behav Pediatr; 2020 Jan; 41(1):65-70. PubMed ID: 31688658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
